Protects against the main causes of cervical cancer, which claimed the lives of around 350,000 women in 2023, of which over 90% are in low- and middle-income countries.
Protects against the main causes of cervical cancer, which claimed the lives of around 350,000 women in 2023, of which over 90% are in low- and middle-income countries.
Human papillomavirus (HPV) vaccine coverage in the 57 lower-income countries supported by Gavi increased from 4% in 2019 to 8% in 2022 and 16% in 2023. This was largely driven by new countries introducing the vaccine into their national immunisation programmes. By end 2023, 38 countries had successfully launched their HPV vaccine national programme with Gavi support, fully immunising more than 27.3 million girls since 2014, which translates to over 605,000 future cervical cancer deaths averted with Gavi support.
In a WHO position paper released in December 2022, the Strategic Advisory Group of Experts on Immunization (SAGE) recommended a one- or two-dose schedule for HPV vaccine. A single dose schedule greatly simplifies delivery of the vaccine, as you only need to reach a girl one time for full protection. In response to this potential gamechanger for Gavi’s HPV vaccine programme – and to overcome the challenges and impact of the COVID-19 pandemic on HPV vaccine coverage – in December 2022, the Gavi Board approved the revitalisation of Gavi’s HPV vaccine programme with a US$ 600+ million investment through 2025. With additional funding in place, the Alliance has set an ambitious goal to reach over 86 million girls with HPV vaccine by end of 2025, aiming to avert over 1.4 million future deaths from cervical cancer.
Cervical cancer is the fourth most common cancer in women globally, causing more than 209,000 deaths in 2022 in lower-income countries. However, HPV is associated with over 90% of these cancers, and vaccination provides high protection against cervical cancer. HPV vaccine has among the highest impact of all Gavi-supported vaccines, with 17.4 deaths averted per 1,000 children vaccinated, and is one of the key interventions towards achieving the global strategy for cervical cancer elimination.
HPV vaccination is critical to reducing cervical cancer, especially in lower-income countries with a high disease burden and less developed cervical cancer screening and treatment programmes. It is also a bridge to improving women’s and girls’ health through increased touchpoints with health services, and therefore an opportunity to positively impact gender equity.
Historically, the high cost of HPV vaccine, limited supply and challenges of reaching adolescent girls to deliver immunisation have been barriers to introduction in lower-income countries. Gavi is working to bridge the equity gap by providing support for national HPV vaccine introductions and ensuring sustainable prices. Gavi supports routine HPV vaccine delivery to a single cohort of girls (e.g. aged 9 years); and a multi-age cohort (MAC) (e.g. aged 10–14) in the year of introduction.
By (1) accelerating quality introductions; (2) rapidly improving global and national coverage; and (3) generating long-term programmatic sustainability, the revitalisation will allow Gavi to dedicate additional funding to help countries and partners reach more girls than ever with this life-saving vaccine. Support available under the US$ 600+ million revitalisation initiative includes expanded funding for vaccine purchasing, introduction and campaign activity costs, and adoption of the single dose-schedule; and expanded technical assistance from partners at regional, national and local levels. Gavi-eligible countries can also utilise health system strengthening (HSS) funding to develop tailored approaches to improve and sustain HPV vaccine coverage.
Lastly, Gavi is investing in implementation research focused on: strengthening integration of services for adolescents; integration of cervical cancer elimination strategies; and strengthening measurement of HPV vaccine coverage.
Gavi currently procures three HPV vaccines that have been prequalified by WHO. After severe supply constraints starting in 2017, HPV vaccine supply outlook is improving – supported by rapid uptake of the single-dose schedule, ramped up production from suppliers and WHO prequalification of new HPV vaccine products.
Not only does HPV vaccine prevent a major cause of female mortality, HPV vaccine delivery is also a touchpoint between adolescent girls and health services which can act as a bridge to improving women’s and girls’ health across the life course. It is an opportunity to build adolescents’ knowledge and trust in the healthcare system; deliver other essential health and education services; and empower girls through involving them in programme design and social mobilisation activities.
Social and cultural norms, and the unequal status of women in many societies, can reduce the chances of children and adolescents being vaccinated, by preventing girls and their caregivers from accessing immunisation services. For example, school-based vaccination programmes may miss girls who are not able to attend school due to gender-related barriers. Therefore, Gavi is investing in innovative approaches to reach out-of-school girls, and to achieve high and equitable coverage.
Wastewater helps monitor cancer-causing HPV
Researchers in Uruguay say wastewater monitoring of the human papillomavirus (HPV) can give important information about its presence in the population.
From vaccines to screenings: how Uzbekistan is transforming cancer care for women
By addressing cervical cancer prevention and expanding efforts to tackle breast cancer, Uzbekistan is setting an example for public health strategies in Central Asia.
Angolans spread the word: cervical cancer is vaccine-preventable
Cervical cancers account for 19% of all new cancer diagnoses in Angola. But a growing movement is trying to spread awareness of the fact that a single dose of human papillomavirus vaccine – soon to be publicly available across the country – can…
HPV increases risk of heart disease, finds study of 250,000 patients
New meta-analysis suggests that the HPV vaccine could not only protect us from cervical cancer, but heart problems too.
Lesotho steps up fight against cervical cancer
Lesotho has one of the world’s highest cervical cancer rates – but with enhanced HPV vaccination and screening campaigns, and a brand-new cancer hospital now under construction, women’s prospects are looking up.
HPV vaccine cuts risk of cervical cancer by two thirds in New Zealand
Ramped-up HPV vaccination and self-testing could bring the country within reach of a cervical cancer-free future.
In Kenya’s Kibra, nurses carry the HPV vaccine gospel
In the informal settlement often described as Africa’s largest slum, social realities make it trickier to mainstream the cancer-blocking jab. Nurse Lencer Akinyi and her colleagues are not backing down.
Mozambique’s doctors join race to reach girls who missed out on vaccination against cervical cancer
Private and hospital doctors are taking up the campaign – and there are signs are that they’re making inroads.
A leader’s promise: protecting Nigeria’s girls from cervical cancer
Swirling misinformation risked hobbling uptake of the cancer-blocking HPV vaccine in his community, so local leader Michael Nyam Sila got to work.
A school principal’s fight against cervical cancer in Nigeria
A healthy body is essential for achieving life’s goals, Afodia Yusuf tells her girls, as she urges them to get their dose of the human papillomavirus vaccine.
A healthier future for girls in Nigeria: Preventing cervical cancer through routine immunisation
Delivering the HPV vaccine to Nigeria’s most fragile communities is no small feat.
The Nigerian cleric on a mission to protect girls from cervical cancer
When Koranic scholar Sheikh Dr Ismail Zakariyya Al-Kashnawii from Katsina state got his daughters vaccinated against the human papillomavirus, he wasn’t just protecting them, he was setting an example.
